Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3Phase 4 1Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 7Recurrence 5Neoplasms 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Diseases 1Primary Myelofibrosis 1Neoplasms by Site 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Genital Diseases 1COVID-19 1

Interventions

Rituximab 66Cyclophosphamide 46Vincristine 40Doxorubicin 40Prednisone 35Etoposide 19Radiotherapy 14Gemcitabine 13Peripheral Blood Stem Cell Transplantation 12Filgrastim 12Cytarabine 12Lenalidomide 11Carmustine 10VAP-cyclo protocol 9Prednisolone 9Oxaliplatin 9Melphalan 9Methotrexate 7Ifosfamide 7Mitoxantrone 6Bleomycin 6polatuzumab vedotin 5R-CHOP protocol 4Methylprednisolone 4Injections 4Granulocyte Colony-Stimulating Factor 4Cyclosporine 4Cisplatin 4Carboplatin 4pegfilgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Large B-Cell, Diffuse × selinexor × Clear all
NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 3 Recruiting
390 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡